DivestmentMay 7, 2026, 04:42 PM
Becton Dickinson Completes Biosciences Spin-off; Reports Q2 Net Loss $311M
AI Summary
Becton Dickinson completed the spin-off of its Biosciences and Diagnostic Solutions business on February 9, 2026, combining it with Waters Corporation. The company received a $4 billion cash distribution from the spin-off entity, utilizing $2 billion for accelerated share repurchases and $2 billion for debt repayments. For the three months ended March 31, 2026, BD reported a net loss of $311 million, primarily driven by a $274 million loss from discontinued operations, despite a revenue increase to $4.714 billion. The company also faces significant ongoing legal proceedings and recently received FDA Warning Letters for two manufacturing facilities.
Key Highlights
- Completed spin-off of Biosciences and Diagnostic Solutions business on Feb 9, 2026.
- Received $4 billion cash from spin-off, used $2 billion for ASR, $2 billion for debt.
- Q2 Net Loss $311M, primarily due to $(274)M from discontinued operations.
- Q2 Revenues from continuing operations rose to $4.714B from $4.480B YoY.
- Q2 Diluted EPS $(1.11) vs. $1.07 YoY.
- Defending ~6,995 hernia and ~3,250 implantable port product liability claims.
- Received FDA Warning Letters for San Diego and El Paso facilities.
- Board authorized additional 10M share repurchase program on Jan 27, 2026.